Pharma

Dec 27 2017

China – s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts #anabolic #pharma

#chinese pharmaceutical companies # China’s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts The world’s largest pharmaceutical companies are facing a roadblock in China as a state-led campaign to slash drug prices has triggered a slowdown in sales growth. One of the biggest problems: China’s government-run health insurance funds, which are struggling to keep up with an ageing population and surging incidence of diseases like cancer or diabetes. As they grapple with tighter budgets and a slowing economy, many of these funds are capping reimbursements to patients and pushing local authorities to negotiate with companies to lower drug prices. …

Dec 2 2017

China – s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts #pharma #bio

#chinese pharmaceutical companies # China’s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts The world’s largest pharmaceutical companies are facing a roadblock in China as a state-led campaign to slash drug prices has triggered a slowdown in sales growth. One of the biggest problems: China’s government-run health insurance funds, which are struggling to keep up with an ageing population and surging incidence of diseases like cancer or diabetes. As they grapple with tighter budgets and a slowing economy, many of these funds are capping reimbursements to patients and pushing local authorities to negotiate with companies to lower drug prices. …

Nov 13 2017

UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #pharmaceutical #companies #market #share

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …

Nov 8 2017

China – s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts #pharma #test

#chinese pharmaceutical companies # China’s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts The world’s largest pharmaceutical companies are facing a roadblock in China as a state-led campaign to slash drug prices has triggered a slowdown in sales growth. One of the biggest problems: China’s government-run health insurance funds, which are struggling to keep up with an ageing population and surging incidence of diseases like cancer or diabetes. As they grapple with tighter budgets and a slowing economy, many of these funds are capping reimbursements to patients and pushing local authorities to negotiate with companies to lower drug prices. …

Sep 30 2017

UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #pharma #regulatory

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …

Sep 9 2017

China – s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts #french #pharmaceutical #companies

#chinese pharmaceutical companies # China’s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts The world’s largest pharmaceutical companies are facing a roadblock in China as a state-led campaign to slash drug prices has triggered a slowdown in sales growth. One of the biggest problems: China’s government-run health insurance funds, which are struggling to keep up with an ageing population and surging incidence of diseases like cancer or diabetes. As they grapple with tighter budgets and a slowing economy, many of these funds are capping reimbursements to patients and pushing local authorities to negotiate with companies to lower drug prices. …

Aug 14 2017

UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #mayne #pharma

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …

May 28 2017

UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #top #50 #pharmaceutical #companies

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …

May 17 2017

China – s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts #spectrum #pharma

#chinese pharmaceutical companies # China’s Drug-Price Cuts Are Hitting Big Pharma Where It Hurts The world’s largest pharmaceutical companies are facing a roadblock in China as a state-led campaign to slash drug prices has triggered a slowdown in sales growth. One of the biggest problems: China’s government-run health insurance funds, which are struggling to keep up with an ageing population and surging incidence of diseases like cancer or diabetes. As they grapple with tighter budgets and a slowing economy, many of these funds are capping reimbursements to patients and pushing local authorities to negotiate with companies to lower drug prices. …

May 13 2017

UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ #global #pharmaceutical #industry

#sankyo pharma # UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ Times have been tough for Daiichi Sankyo, and they’re about to get tougher for some of the Japanese company’s U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, with more layoffs expected in mid-April. The cutbacks are part of a revamp at Daiichi’s U.S. business, based in Parsippany, NJ. The reasons for cutbacks are clear: Daiichi’s exclusivity on the cholesterol drug Welchol expires in June, and a bigger product–the blood pressure drug Benicar–loses its lock on the market next year. That …